On Friday, Relmada Therapeutics Inc (NASDAQ: RLMD) opened lower -12.51% from the last session, before settling in for the closing price of $0.74. Price fluctuations for RLMD have ranged from $0.24 to $4.47 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 34.72% at the time writing. With a float of $27.81 million, this company’s outstanding shares have now reached $30.17 million.
Let’s determine the extent of company efficiency that accounts for 17 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Relmada Therapeutics Inc (RLMD) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Relmada Therapeutics Inc is 16.22%, while institutional ownership is 25.45%. The most recent insider transaction that took place on Sep 11 ’24, was worth 153,707. In this transaction Chief Executive Officer of this company bought 51,407 shares at a rate of $2.99, taking the stock ownership to the 384,024 shares. Before that another transaction happened on Sep 09 ’24, when Company’s Chief Executive Officer bought 55,579 for $2.71, making the entire transaction worth $150,619. This insider now owns 299,603 shares in total.
Relmada Therapeutics Inc (RLMD) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 34.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.94% during the next five years compared to 0.68% growth over the previous five years of trading.
Relmada Therapeutics Inc (NASDAQ: RLMD) Trading Performance Indicators
Check out the current performance indicators for Relmada Therapeutics Inc (RLMD). In the past quarter, the stock posted a quick ratio of 4.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.65, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -1.48 in one year’s time.
Technical Analysis of Relmada Therapeutics Inc (RLMD)
Looking closely at Relmada Therapeutics Inc (NASDAQ: RLMD), its last 5-days average volume was 11.57 million, which is a jump from its year-to-date volume of 1.57 million. As of the previous 9 days, the stock’s Stochastic %D was 90.47%. Additionally, its Average True Range was 0.08.
During the past 100 days, Relmada Therapeutics Inc’s (RLMD) raw stochastic average was set at 12.81%, which indicates a significant decrease from 78.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 260.88% in the past 14 days, which was lower than the 276.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3147, while its 200-day Moving Average is $1.8515. However, in the short run, Relmada Therapeutics Inc’s stock first resistance to watch stands at $0.7316. Second resistance stands at $0.8181. The third major resistance level sits at $0.8989. If the price goes on to break the first support level at $0.5643, it is likely to go to the next support level at $0.4835. Now, if the price goes above the second support level, the third support stands at $0.3970.
Relmada Therapeutics Inc (NASDAQ: RLMD) Key Stats
There are currently 33,192K shares outstanding in the company with a market cap of 21.41 million. Presently, the company’s annual sales total 0 K according to its annual income of -79,980 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -18,660 K.
